Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Defence Therapeutics Inc. ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum ® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company's path forward.

Dear Shareholders, Defence Therapeutics is entering an exciting new stage in its evolution, and I am honoured to have the opportunity to lead the company forward. My first month as CEO has been focused on deepening my understanding of our science, sharpening our strategy and identifying our highest-value opportunities. This work has reinforced my conviction that our Accum® drug-delivery technology is differentiated and has significant potential to enhance a broad range of oncology therapeutics.

Defence is a biotechnology company in a somewhat atypical position: we have been publicly funded through much of the development of our technology platform. This has enabled us to retain control of our technology, access the capital needed to advance it, and give investors the opportunity to join us in building a differentiated precision drug-delivery company. Earlier this year, Defence strengthened its financial position through a successful capital raise, giving us the resources to prepare the company for its next stage of development. Since then, we have strengthened our leadership team, expanded our Board of Directors, made key scientific hires, invested in laboratory capabilities, and accelerated our radiotherapeutics strategy. With this foundation in place, I believe Defence is well positioned for an important period of progress and growth.

We will pursue this through two complementary paths: advancing partnered programs that evaluate and leverage the potential of Accum® across next-generation biologic drugs, while building a focused pipeline of internally developed Accum®-enabled therapeutics.

Sharpening Our Strategy: Over the past several years, our founding CEO, Sébastien Plouffe, and our scientific teams have built a broad body of work around Accum® and explored its potential across multiple therapeutic applications. As Sébastien transitions into his role as Executive Chairman, we are fortunate to retain his experience and commitment to the company. My responsibility as the incoming CEO is to build on that foundation while bringing increased focus to where we invest our people and capital. This means making choices. Biotechnology companies rarely have the resources to pursue every scientifically interesting opportunity. The companies that create lasting value identify the areas where their science provides a meaningful advantage, generate the evidence required to validate that advantage, and focus resources on those opportunities. That is the approach we are taking at Defence Therapeutics.

Our development strategy is focused on three core areas: Accum®-enhanced ADCs; Accum®-enabled radiotherapeutics; and Defining the path forward for our clinical-stage AccuTOX® program. Establishing Accum® as an ADC-Enhancing Technology: Antibody-drug conjugates (ADCs) have become one of the most important and rapidly evolving therapeutic modalities in oncology. Despite significant innovation in antibodies, targets, linkers and payloads, efficient intracellular delivery of the therapeutic payload remains an important challenge and an opportunity to further improve ADC performance. This is the problem Accum® was designed to address. Our studies to date have demonstrated Accum®'s potential to improve intracellular delivery and enhance ADC activity, including the potential for greater anti-tumour activity at lower doses. Our priority now is to evaluate this potentia...